A new study aimed at reducing racial and ethnic disparities in diabetes diagnosis was conducted by a team of physician-scientists at the Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center (BIDMC).
Diabetes is a leading cause of death and disability in the United States, affecting more than 34 million adults and generating $330 billion in annual healthcare expenditures. Excess body weight is one risk factor that increases one’s odds of developing diabetes, and federal guidelines recommend starting screening at age 35 for all overweight adults – defined as those who have a body mass index (BMI) of 25 or higher.
However, Asian, Hispanic, and Black Americans are at increased risk for diabetes at lower weights and younger ages than white Americans, according to the study, which was published in the Annals of Internal Medicine.
Finding the Disparities in Diabetes Diagnosis
The team used statistical modelling to determine the BMI levels and age at which the prevalence of diabetes in racial and ethnic minority populations in the United States is equivalent to the prevalence of diabetes in white Americans considered at risk of diabetes. The team’s findings suggest that screening Asian, Hispanic, and Black Americans for diabetes at lower BMI and younger ages than white Americans has the potential to reduce the rate of undiagnosed diabetes in these groups and as a result, improve health equity in diabetes care.
“The simplicity of a single screening threshold for all Americans is alluring, but it is deeply inequitable,” says senior author Dhruv Kazi, MD, MSc, MS, associate director of the Smith Center and associate professor of medicine at Harvard Medical School. “Our findings suggest that Asian, Hispanic, and Black Americans may need to get screened at lower BMI or younger ages than white Americans. If the current thresholds are universally applied, without accounting for differential risk in racial/ethnic groups, clinicians may underdiagnose diabetes in Asian, Hispanic, and Black Americans. On the other hand, applying a more tailored approach may allow reduce rates of undiagnosed diabetes and produce population wide improvements in diabetes care.”
Kazi and colleagues used a long-running, nationally representative survey from the Centers for Disease Control and Prevention called the National Health and Nutrition Examination Survey (NHANES) to examine the prevalence of diabetes by race/ethnicity, body mass index (BMI), and age. Then, the scientists used regression modelling to determine the BMI at which the prevalence of diabetes in 35-year-old Asian Americans, Black Americans and Hispanic Americans, respectively, is equivalent to the prevalence of diabetes in 35-year-old white Americans with a BMI of 25 kg/m2.
“We found that a more equitable approach would be to offer screening starting at a BMI of 20kg/m2 to Asian Americans ages 35 to 70, and at 18.5 kg/m2 in Hispanic and Black Americans in this age group,” says first author Rahul Aggarwal, MD, an internal medicine resident at BIDMC. “We also found that among individuals from racial and ethnic minority populations with overweight or obesity, it would be equitable to offer diabetes screening starting in the early 20s rather than waiting till they are 35 years old. Delayed diagnosis and inadequate treatment of diabetes can produce catastrophic consequences, jeopardizing one’s heart, kidney, eyes, and limbs. But it doesn’t affect all of us equally – there are striking disparities that are largely the legacy of structural racism. Fixing the health disparities for Americans with diabetes will require a range of strategic investments in health care and efforts to reduce structural inequities. Making screening more equitable is a place to start, as it ensures that individuals with diabetes can receive preventive care and treatment in a timely manner and avert the most catastrophic consequences of diabetes.”
Co-authors included Rahul Aggarwal, MD; Robert W. Yeh, MD, MSc; Nicholas Chiu, MD, MPH; Rishi Wadhera, MD, MPP, MPhil; and Changyu Shen, PhD of the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, BIDMC; Yang Song, MS, of Harvard Medical School; and Kirsten Bibbins-Domingo of University of California, San Francisco.
This study was supported by the Richard A. and Susan F. Smith Center for Outcomes Research. Rishi K. Wadhera receives research support from the National Heart, Lung, and Blood Institute. He is a consultant for Abbott, and has previously served as consultant for Regeneron, outside the submitted work. Robert W. Yeh receives consulting and research grants from AstraZeneca. The rest of the authors have no disclosures.